Ikaria Inc, Hampton, NJ, has completed patient enrollment for its phase III trial investigating the use of inhaled nitric oxide in premature infants with bronchopulmonary dysplasia.
Ikaria completes patient enrollment for phase III trial for bronchopulmonary dysplasia